Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page


Medical Advocates
Pegylated Interferon alfa-2b (PEG-INTRON)
  HCV Conference Data

 12th International Symposium on Viral Hepatitis and :Liver
    Disease
 3tf IAS Conference
11th CROI
XV International AIDS Conference
11th Conference on Retroviruses and Opportunistic
   Infections


 		  
Peg Inf Alfa-2b_HBC=Primal Main Page Main New/Newsworthy Home Page
Last Update:  July 19, 2006  
Documents identified with this icon  are in Portable Document Format (PDF) and require the  Adobe Acrobat Reader 5 .
12th International Symposium on Viral Hepatitis
 and :Liver Disease
  • Effectiveness and tolerability of pegintron(r) in combination with rebetol(r) in real life:
    the pegintrust study
    Adler M., Bastens . B. Colle . I.,  et al
    •  
         Abstract
  • Novel sustained release formulation of ifn-a-2b improves tolerability and demonstrates potent viral load
    reduction in a phase i/ii hcv clinical trial
    Trepo C., Meyrueix R., Maynard M., et al
    Abstract
  • The efficacy of a 12 weeks course of pegylated interferon alfa 2b (peg-ifn) and ribavirin (rbv) is similar to a
    standard 24 weeks course, regardless of basal viremic level
     Bonardi R., Manca A, Tabone M.,  et al
    Abstract
3rd IAS Conference
 
  • Efficacy of acute HCV treatment with peg-interferon a-2b and ribavirin in HIV infected patients
    Kruk A.
     Abstract
11th CROI
 
XV International AIDS Conference
 
HCV Infection
 
  • Moderate dose of PegInterferon alfa-2b in combination with ribavirin in the treatment of HCV
    patients with or without HIV
         C Sarmento, A Horta, H Coelho, O Vasconcelos, et al.
         Abstract
  
11th Conference on Retroviruses and Opportunistic
Infections
HIV/HCV Infection Disease
  • Final Results of ANRS HC02-RIBAVIC: A Randomized Controlled Trial of Pegylated-Interferon-
    alfa    -2b plus Ribavirin vs Interferon-alfa-2b plus Ribavirin for the Initial Treatment of Chronic Hepatitis C
    in HIV Co-infected Patients
         C Perronne, F Carrat, F Bani-Sadr, et al 
    Abstract